BR9709524A - Anticorpos contra um complexo de cd4 e um domìnio receptor de quimiocina e seu uso contra infecções de hiv - Google Patents

Anticorpos contra um complexo de cd4 e um domìnio receptor de quimiocina e seu uso contra infecções de hiv

Info

Publication number
BR9709524A
BR9709524A BR9709524-9A BR9709524A BR9709524A BR 9709524 A BR9709524 A BR 9709524A BR 9709524 A BR9709524 A BR 9709524A BR 9709524 A BR9709524 A BR 9709524A
Authority
BR
Brazil
Prior art keywords
antibodies
hiv
immunodeficiency virus
directed
primary isolates
Prior art date
Application number
BR9709524-9A
Other languages
English (en)
Other versions
BRPI9709524B8 (pt
BRPI9709524B1 (pt
Inventor
Chang Yi Wang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/808,374 external-priority patent/US5961976A/en
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of BR9709524A publication Critical patent/BR9709524A/pt
Publication of BRPI9709524B1 publication Critical patent/BRPI9709524B1/pt
Publication of BRPI9709524B8 publication Critical patent/BRPI9709524B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção:<B>"ANTICORPOS CONTRA UM COMPLEXO DE CD4 E UM DOMìNIO RECEPTOR DE QUIMIOCINA E SEU USO CONTRA INFECçõES DE HIV"<D>. Esta invenção é dirigida a anticorpos monoclonais produzidos pelo uso de linfócitos T que expressam CD4, tais como células T mononucleares de sangue periférico, timócitos, esplenócitos e células de linhagem de célula T derivadas de leucemia ou de linfoma tais como HPB-ALL ou SUP-T como o imunogênio de acordo com os protocolos e os procedimentos de seleção descritos. Os anticorpos monoclonais da presente invenção são caracterizados por sua capacidade de neutralizar isolados primários <MU>in vitro<MV> e <MU>in vivo<MV> de Vírus da Imunodeficiência Humana (HIV) e vírus da imunodeficiência relacionados. Os anticorpos são dirigidos contra um complexo antígeno de célula hospedeira que compreende proteína CD4 em associação com domínios provenientes de receptores de quimiocina e têm amplas atividades neutralizadoras contra isolados primários provenientes de todos os clados de HIV tipo 1 (HIV-1) e isolados primários de HIV tipo 2 (HIV-2) e Vírus da Imunodeficiência Simiana (SIV). A presente invenção é também dirigida a um processo de seleção e de produção de tais anticorpos, hibridomas que secretam tais anticorpos, composições farmacêuticas que compreendem tais anticorpos e processos para prevenção pré-e pós-exposição de infecção por vírus da imunudeficiência em primatas, inclusive seres humanos, por tais anticorpos cujos alvos primários são linfócitos que expressam CD4.
BRPI9709524A 1996-06-03 1997-06-03 processo para a produção de um anticorpo para células t que expressam cd4 BRPI9709524B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65714996A 1996-06-03 1996-06-03
US08/808,374 US5961976A (en) 1996-06-03 1997-02-28 Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US08/867,149 US5912176A (en) 1996-06-03 1997-06-02 Antibodies against a host cell antigen complex for pre and post exposure protection from infection by HIV
PCT/US1997/009449 WO1997046697A2 (en) 1996-06-03 1997-06-03 Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections

Publications (3)

Publication Number Publication Date
BR9709524A true BR9709524A (pt) 2000-05-09
BRPI9709524B1 BRPI9709524B1 (pt) 2016-11-01
BRPI9709524B8 BRPI9709524B8 (pt) 2021-05-25

Family

ID=27417977

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9709524A BRPI9709524B8 (pt) 1996-06-03 1997-06-03 processo para a produção de um anticorpo para células t que expressam cd4

Country Status (10)

Country Link
EP (1) EP0910659B1 (pt)
JP (1) JP2000511775A (pt)
CN (1) CN1227610A (pt)
AT (1) ATE335835T1 (pt)
BR (1) BRPI9709524B8 (pt)
CA (1) CA2256306C (pt)
DE (1) DE69736474T2 (pt)
DK (1) DK0910659T3 (pt)
ES (1) ES2270461T3 (pt)
WO (1) WO1997046697A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
WO2000040964A1 (en) * 1999-01-08 2000-07-13 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Inhibition of cd4-ccr5 interaction
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
EP1723178A4 (en) 2004-03-12 2007-12-12 Human Genome Sciences Inc HUMAN G-PROTEIN CHEMOKIN RECEPTOR (CCR5) HDGNR10
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
CN102649818B (zh) * 2011-02-25 2014-10-08 厦门大学 抗cd4蛋白的单克隆抗体及其活性片段及用途
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
EP3683233A1 (en) * 2015-03-20 2020-07-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to gp120 and their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0353894A (ja) * 1989-07-21 1991-03-07 Calpis Food Ind Co Ltd:The 抗ヒトｃｄ４ペプチドに対するモノクローナル抗体
AU6080794A (en) * 1992-12-31 1994-08-15 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
WO1996041884A1 (en) * 1995-06-09 1996-12-27 Institut Français De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom) Means for detecting and preventing hiv infection involving use of receptors or binding sites capable of interacting with gp120
AU728512B2 (en) * 1996-04-02 2001-01-11 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells

Also Published As

Publication number Publication date
CN1227610A (zh) 1999-09-01
DE69736474D1 (de) 2006-09-21
ATE335835T1 (de) 2006-09-15
DK0910659T3 (da) 2006-11-27
BRPI9709524B8 (pt) 2021-05-25
EP0910659A2 (en) 1999-04-28
JP2000511775A (ja) 2000-09-12
ES2270461T3 (es) 2007-04-01
DE69736474T2 (de) 2007-01-18
EP0910659B1 (en) 2006-08-09
WO1997046697A3 (en) 1997-12-11
WO1997046697A2 (en) 1997-12-11
CA2256306C (en) 2011-03-29
CA2256306A1 (en) 1997-12-11
BRPI9709524B1 (pt) 2016-11-01

Similar Documents

Publication Publication Date Title
BR9709524A (pt) Anticorpos contra um complexo de cd4 e um domìnio receptor de quimiocina e seu uso contra infecções de hiv
Bures et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa
Bastiani et al. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions
LYERLY et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC
Amadori et al. B-cell activation and HIV-1 infection: deeds and misdeeds
Sattentau et al. The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule
Mayr et al. Non-neutralizing antibodies targeting the V1V2 domain of HIV exhibit strong antibody-dependent cell-mediated cytotoxic activity
Rusert et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
DK0479909T3 (da) Bispecifikke reagenser til AIDS-behandling
Amadori et al. CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients.
Gershoni et al. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
Wang et al. Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex
Duval et al. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils
Tanabe-Tochikura et al. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro
Fujita et al. Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif
Jagodzinski et al. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes
Marschang et al. HIV and complement: role of the complement system in HIV infection
Sei et al. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study
Pal et al. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A
EP0725654A1 (en) Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
Sugano et al. Human monoclonal antibody against glycoproteins of human immunodeficiency virus
Jinno-Oue et al. The synthetic peptide derived from the NH2-terminal extracellular region of an orphan G protein-coupled receptor, GPR1, preferentially inhibits infection of X4 HIV-1
Chen et al. HIV-1 gp41 enhances major histocompatibility complex class I and ICAM-1 expression on H9 and U937 cells
Wu et al. Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37 DA LEI 9.279/96, INDEFIRO O PRESENTE PEDIDO COM BASE O ARTIGO 24 DA LEI 9.279 DE 14/05/1996.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/11/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/1997 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 03/06/2017